Secondary prevention after intracerebral haemorrhage

Author:

Toffali Maddalena1ORCID,Carbone Federico23,Fainardi Enrico4,Morotti Andrea5ORCID,Montecucco Fabrizio23ORCID,Liberale Luca23ORCID,Padovani Alessandro15

Affiliation:

1. Neurology Unit, Department of Clinical and Experimental Sciences University of Brescia Brescia Italy

2. First Clinic of Internal Medicine, Department of Internal Medicine University of Genoa Genoa Italy

3. IRCCS Ospedale Policlinico San Martino Genoa—Italian Cardiovascular Network Genoa Italy

4. Neuroradiology Unit, Department of Experimental and Clinical Biomedical Sciences University of Florence Florence Italy

5. Department of Neurological Sciences and Vision, Neurology Unit ASST Spedali Civili Brescia Italy

Abstract

AbstractBackgroundIntracerebral haemorrhage (ICH) has high mortality in the acute phase and poor functional outcome in the majority of survivors. ICH recurrence is a major determinant of long‐term prognosis and is the most feared complication of antithrombotic treatment. On the other hand, ICH patients are at high risk of future ischaemic vascular events.MethodsThis narrative review provides a critical analysis of the current knowledge on the topic. We performed a Pubmed search with the following terms ‘intracerebral haemorrhage’, ‘stroke’, ‘outcome’, ‘secondary prevention’, ‘anticoagulation’ and ‘atrial fibrillation’, including only English written studies with no time restrictions.ResultsBlood pressure management is the cornerstone of secondary ICH prevention, regardless of ICH location or underlying cerebral small vessel disease. Resumption of antiplatelet and anticoagulation therapy is often challenging, with limited evidence from randomized trials. Clinical and imaging predictors can inform the stratification of ICH recurrence risk and might identify patients at very high probability of future haemorrhagic events. This narrative review provides a summary of the main diagnostic tools and therapeutic strategies available for secondary prevention in ICH survivors.ConclusionAppropriate recognition and treatment of modifiable risk factors for ICH recurrence might improve outcomes in ICH survivors. Ongoing randomized trials might provide novel insights and improve long‐term management.

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3